Additional metadata, such as histological (e.g. LUAD, LUSC or SCLC for lung cancer) or molecular subtype (e.g. ER + / HER2+ status for breast cancer), for each cancer was extracted for downstream analysis. This evidence concerns the gene ERBB2 and lung carcinoma.